MiMedx Updates Second Quarter Information
Second quarter revenue of $45.7 million grew almost 80%, which was above analyst consensus and only $321,000 below the Company’s high end guidance. While the Company has often exceeded its guidance over the last three years, there have been a number of quarters where the revenue was in the upper end of the range as it was this quarter read more
Stryker to Participate in Canaccord Genuity 35th Annual Growth Conference
Kalamazoo, Michigan – August 6, 2015 – Stryker Corporation (NYSE:SYK) will participate in the Canaccord Genuity 35th Annual Growth Conference on Wednesday, August 12, 2015 at the InterContinental Boston. Katherine Owen, Vice President, Strategy and Investor Relations, will represent the Company in a presentation scheduled for 9:30 a.m. Eastern Time.
A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at www.stryker.com.
Mylan Second Quarter 2015 Constant Currency Revenue Increases 36% and Adjusted Diluted EPS Increases 32% to $0.91
Mylan Increases 2015 Adjusted Diluted EPS Guidance Range to $4.15 to $4.35 read more
Sarepta Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 6, 2015– Sarepta Therapeutics, Inc.(NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three and six months ended June 30, 2015, and provided an update of recent corporate developments. read more
Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to $5.76 Billion and 29% Growth in Non-GAAP EPS to $4.41
Adjusted EBITDA Increases 203% to $2.6 Billion in Second Quarter 2015 -Strong Performance Across All Businesses –Q2 2015 GAAP Loss Per Share of $0.80 — Integration of Actavis-Allergan On-Track — read more
Novo Nordisk increased operating profit in Danish kroner by 57% in the first six months of 2015 to DKK 26.3 billion
16% local currency operating profit growth adjusted for the NNIT divestment/Sales increased by 25% in Danish kroner and by 9% in local currencies to DKK 52.3 billion.
- Sales of Victoza® increased by 41% (22% in local currencies).
- Sales of Levemir® increased by 28% (10% in local currencies).
- Sales in North America increased by 35% (10% in local currencies).
- Sales in International Operations increased by 26% (17% in local currencies).
- Sales in Region China increased by 25% (3% in local currencies). read more